Zegfrovy 150 mg Tablet contains Sunvozertinib, a next-generation EGFR tyrosine kinase inhibitor (TKI) developed to specifically target EGFR exon 20 insertion mutations in patients with non-small cell lung cancer (NSCLC). https://www.drugsgeneral.com/zegfrovy-150-mg-tablet/